Clinical Trials
2 trialsNCT06573424 2025-05-01
Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Completed
NCT04777162 2021-03-04
Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer
Peking University
Phase 2 Unknown